(RxWiki News) The US Food and Drug Administration (FDA) has issued a safety announcement about the type 2 diabetes medication pioglitazone.
Based on an updated FDA review, the agency has concluded that the use of pioglitazone may be tied to an increased risk of bladder cancer.
This medication already contains information on this possible risk. Now, its label will include additional information on the newer studies indicating this risk.
Pioglitazone is approved in combination with diet and exercise to treat type 2 diabetes. It can be found under any of the following brand names: Duetact, Actos, Actoplus Met, Actoplus Met XR and Oseni.
Those with active bladder cancer should not take medication containing pioglitazone. If you have a history of bladder cancer, your health care provider will consider the benefits and risks.
If you are already taking pioglitazone, contact your health care provider if you experience blood or red color in your urine, a new or worsening urge to urinate or pain when urinating. These may be signs or symptoms of bladder cancer.
Speak to your doctor or pharmacist about the risks associated with your medication and any questions you may have.
